ArticleScientific reports2025
Serum peptide biomarkers by MALDI-TOF MS coupled with machine learning for diagnosis and classification of hepato-pancreato-biliary cancers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine Learning-Enhanced MALDI-TOF Mass Spectrometry for Screening HBsAg-Positive Patients.Microorganisms · 2026Article
- Rapid peptide analysis in dried bloodspots to identify novel markers for newborn screening for congenital hypothyroidism.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the potential of peptide mass fingerprints (PMFs) of the serum peptidome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), in combination with machine learning algorithms-support vector machine (SVM) and random forest (RF)-for the diagnosis and classification of hepato-pancreato-biliary (HPB) cancers. Serum samples collected from healthy individuals and patients with various HPB cancers were analyzed to generate PMF profiles. The resulting data were randomly split into training and testing sets. Feature selection on the training set identified 71 informative peptide mass fingerprints, which were then used to construct predictive models using SVM and RF algorithms. Visualization using heatmap, PLS-DA, and multiclass RF analysis showed clear separation between healthy individuals and HPB cancer patients, as well as among different HPB cancer subtypes. Both models achieved high classification performance, with accuracy, AUROC, and MCC values exceeding 0.90 in both training and testing datasets. Notably, the models also exhibited strong multiclass discrimination ability. These findings demonstrate that serum PMF profiling using MALDI-TOF MS, combined with SVM and RF models, enables high-performance, non-invasive detection and classification of HPB cancers, with strong potential to support early diagnosis and inform clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.